^
Association details:
| Biomarker: | GSPT1 deletion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | eragidomide (CC-90009) (GSPT1 degrader, Ubiquitin pathway modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PHARMACODYNAMIC (PD) RESPONSES TO CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD), IN A PHASE 1 DOSE-ESCALATION STUDY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (RR AML)
Published date:
05/14/2020
Excerpt:
A marked reduction in GSPT1 was observed in T and blast cells of most patients after the first dose of CC-90009 at all dose levels,…These clinical findings are consistent with our preclinical studies in which GSPT1 loss culminated in apoptosis, likely through activation of ISR and inhibition of NMD pathways.
